Akari Therapeutics

Akari Therapeutics is a clinical-stage biopharmaceutical company based in London, specializing in the development and commercialization of innovative treatments for rare autoimmune and inflammatory diseases. The company's primary product candidate, Coversin, is a second-generation complement inhibitor currently undergoing Phase II clinical trials for various conditions, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, and atypical hemolytic uremic syndrome. Akari focuses on therapies that target key pathways involved in these diseases, specifically the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. Founded in 2015, Akari aims to provide life-transforming treatments for patients suffering from autoinflammatory conditions.